SCHEMBL1787406

SCHEMBL1787406

COc1ccc(C(=O)c2cc(Br)ccc2C(=O)O)cc1.COc1ccc(C(=O)c2ccc(Br)cc2C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.59
▸ NPSR1 Q6W5P4 3/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ LMNA P02545 2/20 0.59
▸ MAPK1 P28482 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ RXFP1 Q9HBX9 1/20 0.59
▸ AKR1C3 P42330 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.50
▸ AKR1C2 P52895 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ HTT P42858 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ PGR P06401 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679518 0.97 MAPT (0.63) MAPTNPSR1RAB9ALMNAMAPK1
SCHEMBL4676500 0.97 MAPT (0.63) MAPTNPSR1RAB9ALMNAMAPK1
SCHEMBL4844039 0.88 MAPT (0.63) MAPTNPSR1RAB9ALMNAMAPK1
SCHEMBL4124832 0.85 NPC1 (0.68) MAPTNPSR1RAB9ALMNAMAPK1
SCHEMBL4257594 0.83 AKR1C3 (0.70) MAPTLMNAMAPK1AKR1C3NPC1
SCHEMBL8483054 0.82 MAPT (0.67) MAPTNPSR1RAB9ALMNAMAPK1
SCHEMBL4680433 0.82 CYP2C8 (0.59) MAPTRAB9ALMNAMAPK1AKR1C3
SCHEMBL4675271 0.82 CYP2C8 (0.59) MAPTRAB9ALMNAMAPK1AKR1C3
SCHEMBL24149128 0.81 MAPT (0.65) MAPTNPSR1RAB9ALMNAMAPK1
SCHEMBL4839307 0.81 NPC1 (0.58) MAPTNPSR1RAB9ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 — — US disclosed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 — — EP disclosed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 — — WO disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 MAPT 3480/4885NPSR1 505/4885RAB9A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback